Navigation Links
Drug to treat lung cancer shows promise

A pill long used around the world to treat dry mouth could help protect against lung cancer in lifelong smokers. The drug appears especially promising for former smokers, who still face a higher-than-usual risk// of lung cancers years after they quit. The preliminary study found that the medicine reduced the risk of new or worsening precancerous growths in the lungs of longtime smokers by about 30% during 7 months of use.

The drug, made by the French company Solvay Pharma, is not available in the US. It is sold in Canada, Europe, China and other countries as Sialor or Sulfarlem and has been on the market for 30 years. The drug appears to work by increasing the body's levels of an enzyme called Gst that ordinarily detoxifies dangerous substances, such as tobacco smoke. Levels of this enzyme can be abnormally low in people long exposed to tobacco.

Experts say large-scale testing will be necessary to show that the approach truly lowers the risk of lung cancer, but they say the latest findings make biological sense. "It's an intriguing, promising finding in a small patient population. When people give up smoking, they retain a substantial risk of lung cancer. Half of newly diagnosed lung cancer is in former smokers. The challenge is helping these people lower their risk." said Dr. Frank J. Rauscher III of the Wistar Institute in Philadelphia.
'"/>




Page: 1

Related medicine news :

1. Thyroid hormone treatment hastens recovery after cardiac surgery
2. Feeding channel created by malaria parasite - a new target for malaria treatments
3. New drug to treat Heart Attack and damaged tissue
4. Now umbilical cord helps in stroke treatment.
5. Now AIDS treatment comes dirt-cheap
6. Breast cancer treatment to be determined by gene test
7. Hemopurifier may revolutionise AIDS treatment
8. New drug helps boost cancer treatment
9. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
10. Experimental treatment for Ebola Virus Shows promising results in mice
11. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... ... Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System ... procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. ...
(Date:3/28/2017)... ... , ... Oily skin is a common and unwelcomed occurrence in people of all ages, genders ... offer to the discussion of dealing with excess skin oil. “Oily skin is a challenge ... that can help remove the oily shine while keeping the skin fresh and clean,” says ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have ... sleep apnea treatment, with or without a referral. Sleep apnea is often left untreated ... daytime sleepiness, morning headaches and chronic snoring. , Dr. Braasch seeks to raise ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... gain site attention and engagement over the household brands of Top-20 pharma by ... will discuss how partnering with the right outsourcing payments provider can provide the ...
(Date:3/27/2017)... ... 27, 2017 , ... Adding to its expanding portfolio of ... and NEJM Journal Watch, announces the release of NEJM Knowledge+ Pediatrics Board ... of pediatricians from leading medical centers. The content was then reviewed and approved ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... March 27, 2017  iCAD (Nasdaq: ICAD), an ... and radiation therapy for the early identification and ... Detection received Premarket Approval (PMA) from the U.S. ... is a first-of-its-kind, concurrent-read computer aided detection solution ... latest innovation available on the PowerLook® Breast Health ...
(Date:3/27/2017)... 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), a ... liver diseases in children, today reported financial results ... December 31, 2016 and provided an update on ... to make progress during the fourth quarter of ... our non-human primate safety study, and with our lead ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 Abdominal ... to reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% from 2016 ... revenue, and is projected to dominate the market during the study period. ... ... Logo ...
Breaking Medicine Technology: